2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2308 Bone marrow CD138-negative transcriptomics reveal tumor burden-dependent immune exhaustion and microenvironment dysfunction in multiple myeloma

Maher Albitar, M.D., Sally Agersborg, MD, PhD2, Ahmad Charifa, MD3, Adam Albitar, MD4, Pooja Phull, MD5, Noa Biran, MD6, David Vesole, MD, PhD7, Harsh Parmar, MD8, Joseph Franz, MD9, Andrew Pecora, MD10, Andrew Ip, MD, MS11, Andre Goy, MD12, Frits van Rhee, MD, PhD13, Ajai Chari, MD14, Ivan Borrello, MD15, Thomas Martin, MD16, David S Siegel, MD, PhD17
1 Genomic Testing Cooperative, Lake Forest, California, United States
2 Genomic Testing Cooperative, Lake Forest, California, United States
3 Genomic Testing Cooperative, Lake Forest, California, United States
4 Genomic Testing Cooperative, Lake Forest, California, United States
5 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
6 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
7 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
8 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
9 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
10 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
11 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
12 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States
13 UAMS Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
14 UCSF, San Francisco, California, United States
15 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
16 UCSF, San Francisco, California, United States
17 HMH John Theurer Cancer Center, Hackensack, New Jersey, United States

Introduction: Malignant plasma cells are known to hijack the surrounding bone marrow (BM) microenvironment to accommodate their growth and proliferation. The interaction between plasma cells and their microenvironment plays a major role not only in disease aggressiveness but also in the efficacy of therapeutic approaches. Malignant plasma cells drive BM stromal cells to secrete survival signals that influence osteoclastic activity, vascularity, the immune system, the myeloid/macrophage compartment, checkpoint markers, and adhesion and inflammatory pathways. Studying these microenvironmental changes requires isolation of an adequate number of non-plasma cells; RNA transcriptomic evaluation of this population by next-generation sequencing (NGS) allows assessment of the relevant biological pathways and their interactions. However, such changes are ideally compared to normal bone marrow, which is difficult to obtain and not ethically justifiable to collect for this purpose. To address this, we compared bone marrow microenvironment changes in patients with low versus high MM tumor burden, on the assumption that higher malignant cell burden amplifies its effects on the BM microenvironment.

Methods: Consecutive bone marrow aspiration samples from 1278 patients with multiple myeloma were received for routine clinical evaluation. CD138-positive cells were separated from the remaining cells using a STEMCELL EasySep kit. RNA was isolated from both CD138+ and CD138- fractions and sequenced using a hybrid-capture targeted panel of approximately 1600 genes, together with T-cell receptor (TCR) genes (TRA, TRB, TRG, TRD) and B-cell receptor (BCR) heavy-chain (IGH), kappa (IGK), and lambda (IGL) genes. Gene expression was calculated as transcripts per million (TPM). MiXCR software was used to analyze BCR and TCR repertoires, with expression of each receptor clonotype calculated as a percentage of total expressed RNA for that receptor. Cases were divided into high- and low-MM-burden groups based on the median CD138 mRNA level.

Results: In the CD138- fraction, the high-MM-burden group showed significantly lower expression (LogFDR <-2) of 458 genes relative to the low-burden group, consistent with exhaustion across several pathways: (1) TCR complex (CD3D, CD3E, CD3G, CD247, ZAP70, ITK, PLCG1, CARD11, MALT1, RASGRP1, TCF7, CD2, CD5, CD7, CD8A, CD8B); (2) immune checkpoint (CTLA4, PDCD1, LAG3, HAVCR2/TIM3, TNFRSF4/OX40, ICOS, CD28, CD40LG, TNFRSF14, CD274/PD-L1, FOXP3, IL2RA); (3) B-cell/plasma differentiation factors (PRDM1/BLIMP1, XBP1, BACH2, IKZF1, IKZF3, BCL11B); (4) apoptosis regulators (FAS, FASLG, CASP3, CASP7, CASP8, XIAP, BIRC3, BIRC6, TNFRSF10B, TNFRSF10D, BCL2L2); (5) DNA damage/repair regulators (TP53BP1, BAP1, FBXW7, VHL, WRN, XPA, XPC, ERCC3, ERCC5, CHEK1, STAG2, SMC3, RAD21, NIPBL); (6) cytokines/effectors (IL2, IFNG, GZMB, TNF, IL15, FASLG, IL21R, CCL2, IL6, IL7R, CD40LG); and (7) NF-κB pathway (RELA, NFKB1, NFKB2, CHUK, MAP3K14, BIRC3, TNFAIP3, CYLD, BCL10, CARD11, MALT1).

The high-burden group also showed significant overexpression (LogFDR <-2) of 153 genes, reflecting activation of: (1) ECM structural/remodeling pathways (COL3A1, COL1A2, DCN, POSTN, OMD, IBSP, MMP9); (2) the WNT/osteoblast-suppression axis (WNT5B, WNT4, WNT6, DKK1, PRICKLE1); (3) osteogenic differentiation (SATB2, CDH11, BMP4, TSHR); (4) growth factor signaling (IGF1, IGF1R, HGF, KDR, VEGFC, GHR, LIFR); (5) neural/neurotrophic factors (NGFR, BDNF, NTRK2, NTRK3, CNTN1, CHL1, PCLO, GRIN2B, GABRG2, TENM1, ASTN2, MAP2, SORBS2); (6) cell cycle/proliferation genes (CDK4, PIMREG/FAM64A, UBTF, CCND1); and (7) the Hippo pathway (YAP1, WWTR1/TAZ, TEAD1, TEAD2, TEAD3).

TCR repertoire analysis showed a parallel pattern of exhaustion, with significantly lower utilization of TRAV8-6, TRBV6-8, TRAV26-1, and TRAV8-2 in high-MM-burden cases (LogFDR -3.40, -2.03, -1.85, and -1.82, respectively).

Conclusions: This data shows that malignant plasma cells disrupt normal bone marrow processes, particularly the immune system and structural integrity of the marrow, and that this influence is proportional to MM tumor burden. This suggests that early intervention and therapeutic strategies aimed at protecting the BM microenvironment may be a rational approach.

Maher Albitar, M.D.: Genomic Testing Cooperative - Current equity holder in private company; Genomic Testing Cooperative - Current Employment